



Effect of proteinase inhibition on glucagon-like peptide-2 concentrations in blood samples from healthy cats



Zackery Bieberly, Leah Freilich, Maria Jugan

Department of Clinical Sciences, College of Veterinary Medicine,
Kansas State University, Manhattan, Kansas.

Background

- GLP-2 is an enteroendocrine hormone with intestinal protective and proliferative effects
- GLP-2 secretion is stimulated by enteral nutrition
 - GLP-2 is co-secreted with GLP-1 from intestinal endocrine L-cells
 - The peak secretion time for GLP-1 in cats and humans is between 30 - 75 minutes
 - Glucose-dependent insulintropic polypeptide mediates GLP-2 secretion and is stimulated more by fat than other nutrients in cats
- GLP-2 is rapidly broken down ($T_{1/2} = 7$ minutes in rats and humans) from the active form (1-33) GLP-2 to the inactive form (3-33) GLP-2 by the enzyme dipeptidyl peptidase IV (DPP-IV)
- Previous studies based on human GLP-2 found that use of the proteinase inhibitors Diprotin A and Aprotinin was the only viable method that delayed peptide degradation and resulted in increased measured concentrations
 - Diprotin A is a DPP-IV specific inhibitor
 - Aprotinin is a trypsin inhibitor
- While the sequence of GLP-2 in cats is unknown, GLP-2 is highly conserved, with 100% conservation of the N-terminal sequence across all studied mammalian species

Objective

- To determine the effect of sample collection with or without proteinase inhibition on measured pre- and post-prandial plasma GLP-2 concentrations in healthy cats.

Hypothesis

- Measured GLP-2 concentrations will be significantly greater in samples with proteinase inhibitors added.

Materials and Methods

- Study design: Prospective
- Population: 6 healthy, client-owned cats
 - Eligibility was based on physical exam including a body condition score of 4-6/9, and lack of abnormalities on blood work (CBC, serum chemistry profile)
 - Exclusions: <1 year of age, systemic or GI clinical signs, medications other than preventatives, prescription diets to control historical GI signs
- Sample collection:
 - After a ≥ 10 hour fast a pre-prandial blood sample was obtained
 - The cats were fed a standardized commercial diet (Protein 10.4 g/100 kcal, Fat 7.25 g/100 kcal, CHO 0.12 g/100 kcal) at $\frac{1}{4}$ resting energy requirements
 - A second, 1-hour post-prandial blood sample was obtained
- Sample handling:
 - Blood was collected into chilled EDTA tubes on ice
 - At the time of collection, half of each sample was immediately mixed with 10% volume per blood volume of the proteinase inhibitors Aprotinin and Diprotin A (ILE-PRO-ILE)
 - Samples were immediately centrifuged (temperature controlled), separated, and stored at -80°C
- GLP-2 concentrations were assessed using commercial ELISA tests marketed for cats based on the human sequence of (1-33) GLP-2 (MyBiosource)
 - Monoclonal mouse capture antibody
 - Polyclonal rabbit detection antibody
 - Reported assay detection limits are 0.96 – 2.14 ng/ml with a sensitivity of 0.1 ng/ml in feline samples; however, results using this ELISA have not been published
- All samples were run in duplicate on two 96 well plates
 - Plate one consisted of samples without proteinase inhibitors and six random samples (three from plate one and three from plate two)
 - Plate two consisted of samples with proteinase inhibitors added and six random samples (three from plate one and three from plate two)

Data

- Population:
 - 5 spayed females, 1 castrated male
 - Breeds: 5 domestic short hair, 1 sphinx
 - Median age: 3.5 years (Range 1.5 - 6.9 years)
 - Median weight: 4.35 kg (Range 3.8 - 4.96 kg)
 - Median body condition score: 5/9 (Range 4 - 6/9)



Statistical Analysis

- Data were assessed for normality using the Shapiro-Wilk test
- The concentration of GLP-2 was compared between samples with and without proteinase inhibition using a paired t test
- $p < 0.05$ was considered significant

Data

- GLP-2 was detected in all samples
- Intra-assay variability was 3.1% in plate 1 and 2.56% in plate 2
- Inter-assay variability was 7.83%

Data





Figure 1. Individual cat GLP-2 concentrations in pre-prandial (top) and post-prandial (bottom) plasma samples from healthy cats.

Data

- There was no significant difference in GLP-2 concentration between samples with and without protease inhibitors:
 - Mean pre-prandial concentration with proteinase inhibition 1.92 ng/ml (SD = 0.47) vs 1.93 ng/ml (SD = 0.48) without proteinase inhibition ($p = 0.96$)
 - Mean post-prandial concentration with proteinase inhibition was 1.97 ng/ml (SD = 0.58) vs 1.92 (SD = 0.55) without proteinase inhibition ($p = 0.55$).

Discussion and Conclusions

- GLP-2 was successfully measured using a commercially available ELISA
- Addition of the proteinase inhibitors Aprotinin and Diprotin A at the time of sample collection did not affect measured concentration
- Additional studies are needed to determine whether results are due to differences in secretion or enzymatic GLP-2 degradation in cats compared to humans, other sample handling variables, or specificity of the ELISA to distinguish (1-33) vs (3-33) GLP-2
- The next step of this research is to sequence feline GLP-2 using immunoprecipitation, compared sample concentrations of (1-33) and (3-33) GLP-2 using high performance liquid chromatography and perform GLP-2 ELISA quantification on samples after GLP-2 has been precipitated out, which may provide further insight on the results that were observed.



Acknowledgements

- Student support: Chet Peterson Family Scholarship and KSU CVM Office of Research
- Special thanks to the willing cat volunteers
- Special thanks to Dr. Thomas Schermerhorn and KSU DMP for laboratory space

References

- Burrin DG, Stoll B, Guan X. Glucagon-like peptide 2 function in domestic animals. *Domest Anim Endocrin.* 2003;24:103-122.
- Brubaker PL. Glucagon-like peptide 2 and the regulation of intestinal growth and function. *Comprehensive Physiology.* 2018;8:1185-1210.
- Dube PE, Brubaker PL. Frontiers in glucagon-like peptide 2: multiple actions, multiple mediators. *Am J Physiol Endocrinol Metab.* 2007;293:E460-465.
- Martin GR, Wallace LE, et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. *Am J Physiol.* 2005; 288 (3):G431-G438.